Literature DB >> 22123687

Baseline in vitro activities of the antimalarials pyronaridine and methylene blue against Plasmodium falciparum isolates from Kenya.

John Okombo1, Steven M Kiara, Leah Mwai, Lewa Pole, Eric Ohuma, Lynette Isabella Ochola, Alexis Nzila.   

Abstract

We have analyzed the in vitro activities of pyronaridine and methylene blue against 59 Plasmodium falciparum isolates from Kenya in association with polymorphisms in Pfcrt (codon 76), Pfmdr1 (codon 86), and Pfnhe (full sequence). The median inhibitory concentrations that kill 50% of parasites were 13.5 and 3.3 nM for pyronaridine and methylene blue, respectively. Their activities were not associated with polymorphisms in these genes. The drugs' high in vitro activities indicate that they would be efficacious against Kenyan isolates in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22123687      PMCID: PMC3264213          DOI: 10.1128/AAC.05454-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.

Authors:  R N Price; J Marfurt; F Chalfein; E Kenangalem; K A Piera; E Tjitra; N M Anstey; B Russell
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

2.  In vitro activity of Proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs.

Authors:  Aurélie Pascual; Maud Henry; Sébastien Briolant; Serge Charras; Eric Baret; Rémy Amalvict; Emilie Huyghues des Etages; Michel Feraud; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

3.  Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso.

Authors:  Anyirékun Fabrice Somé; Yves Y Séré; Christian Dokomajilar; Issaka Zongo; Noël Rouamba; Bryan Greenhouse; Jean-Bosco Ouédraogo; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

Review 4.  Update on genetic markers of quinine resistance in Plasmodium falciparum.

Authors:  John Okombo; Eric Ohuma; Stephane Picot; Alexis Nzila
Journal:  Mol Biochem Parasitol       Date:  2011-02-01       Impact factor: 1.759

5.  In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.

Authors:  John Okombo; Steven M Kiara; Josea Rono; Leah Mwai; Lewa Pole; Eric Ohuma; Steffen Borrmann; Lynette Isabella Ochola; Alexis Nzila
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

6.  Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial.

Authors:  Antoinette K Tshefu; Oumar Gaye; Kassoum Kayentao; Ricardo Thompson; Kirana M Bhatt; Sanie S S Sesay; Dorina G Bustos; Emiliana Tjitra; George Bedu-Addo; Isabelle Borghini-Fuhrer; Stephan Duparc; Chang Sik Shin; Lawrence Fleckenstein
Journal:  Lancet       Date:  2010-04-24       Impact factor: 79.321

Review 7.  Methylene blue.

Authors:  Jack Clifton; Jerrold B Leikin
Journal:  Am J Ther       Date:  2003 Jul-Aug       Impact factor: 2.688

Review 8.  Methylene blue as an antimalarial agent.

Authors:  R Heiner Schirmer; Boubacar Coulibaly; August Stich; Michael Scheiwein; Heiko Merkle; Jana Eubel; Katja Becker; Heiko Becher; Olaf Müller; Thomas Zich; Wolfgang Schiek; Bocar Kouyaté
Journal:  Redox Rep       Date:  2003       Impact factor: 4.412

9.  Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial.

Authors:  Yi Poravuth; Duong Socheat; Ronnatrai Rueangweerayut; Chirapong Uthaisin; Aung Pyae Phyo; Neena Valecha; B H Krishnamoorthy Rao; Emiliana Tjitra; Asep Purnama; Isabelle Borghini-Fuhrer; Stephan Duparc; Chang-Sik Shin; Lawrence Fleckenstein
Journal:  PLoS One       Date:  2011-01-18       Impact factor: 3.240

10.  Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum.

Authors:  Bruno Pradines; Sébastien Briolant; Maud Henry; Claude Oeuvray; Eric Baret; Rémy Amalvict; Eric Didillon; Christophe Rogier
Journal:  Malar J       Date:  2010-11-25       Impact factor: 2.979

View more
  10 in total

1.  In Vitro Sensitivity of Pyronaridine in Thai Isolates of Plasmodium falciparum.

Authors:  Kittiya Mahotorn; Peerapan Tan-Ariya; Thunyapit Thita; Toon Ruang-Areerate; Naruemon Sittichot; Nantana Suwandittakul; Mathirut Mungthin
Journal:  Am J Trop Med Hyg       Date:  2018-01-01       Impact factor: 2.345

2.  Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax.

Authors:  Grennady Wirjanata; Boni F Sebayang; Ferryanto Chalfein; Irene Handayuni; Leily Trianty; Enny Kenangalem; Rintis Noviyanti; Brice Campo; Jeanne Rini Poespoprodjo; Jörg J Möhrle; Ric N Price; Jutta Marfurt
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

3.  Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials.

Authors:  Stephan Duparc; Isabelle Borghini-Fuhrer; Carl J Craft; Sarah Arbe-Barnes; Robert M Miller; Chang-Sik Shin; Lawrence Fleckenstein
Journal:  Malar J       Date:  2013-02-21       Impact factor: 2.979

4.  Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine.

Authors:  Aurélie Pascual; Marilyn Madamet; Sébastien Briolant; Tiphaine Gaillard; Rémy Amalvict; Nicolas Benoit; Dominique Travers; Bruno Pradines
Journal:  Malar J       Date:  2015-02-05       Impact factor: 2.979

5.  Plasmodium falciparum susceptibility to standard and potential anti-malarial drugs in Dakar, Senegal, during the 2013-2014 malaria season.

Authors:  Bécaye Fall; Cheikhou Camara; Mansour Fall; Aminata Nakoulima; Pierre Dionne; Bakary Diatta; Yaya Diemé; Boubacar Wade; Bruno Pradines
Journal:  Malar J       Date:  2015-02-06       Impact factor: 2.979

6.  The Plasmodium falciparum chloroquine resistance transporter is associated with the ex vivo P. falciparum African parasite response to pyronaridine.

Authors:  Marylin Madamet; Sébastien Briolant; Rémy Amalvict; Nicolas Benoit; Housem Bouchiba; Julien Cren; Bruno Pradines
Journal:  Parasit Vectors       Date:  2016-02-09       Impact factor: 3.876

7.  Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model.

Authors:  Jérome Dormoi; Sébastien Briolant; Camille Desgrouas; Bruno Pradines
Journal:  Malar J       Date:  2013-04-15       Impact factor: 2.979

8.  A genome wide association study of Plasmodium falciparum susceptibility to 22 antimalarial drugs in Kenya.

Authors:  Jason P Wendler; John Okombo; Roberto Amato; Olivo Miotto; Steven M Kiara; Leah Mwai; Lewa Pole; John O'Brien; Magnus Manske; Dan Alcock; Eleanor Drury; Mandy Sanders; Samuel O Oyola; Cinzia Malangone; Dushyanth Jyothi; Alistair Miles; Kirk A Rockett; Bronwyn L MacInnis; Kevin Marsh; Philip Bejon; Alexis Nzila; Dominic P Kwiatkowski
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

9.  Machine learning models identify molecules active against the Ebola virus in vitro.

Authors:  Sean Ekins; Joel S Freundlich; Alex M Clark; Manu Anantpadma; Robert A Davey; Peter Madrid
Journal:  F1000Res       Date:  2015-10-20

10.  Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection.

Authors:  Thomas R Lane; Christopher Massey; Jason E Comer; Manu Anantpadma; Joel S Freundlich; Robert A Davey; Peter B Madrid; Sean Ekins
Journal:  PLoS Negl Trop Dis       Date:  2019-11-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.